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Abstract. Glial cell line-derived neurotrophic factor 
(GDNF) is a neurotrophic polypeptide, distantly re- 
lated to transforming growth factor-[3 (TGF-[3), origi- 
nally isolated by virtue of its ability to induce dopamine 
uptake and cell survival in cultures of embryonic ven- 
tral midbrain dopaminergic neurons, and more recently 
shown to be a potent neurotrophic factor for motorneu- 
rons. The biological activities and distribution of this 
molecule outside the central nervous system are pres- 
ently unknown. We report here on the mRNA expres- 
sion, biological activities and initial receptor binding 
characterization of GDNF and a shorter spliced variant 
termed GDNF[3 in different organs and peripheral neu- 
rons of the developing rat. Both GDNF mRNA forms 
were found to be most highly expressed in developing 
skin, whisker pad, kidney, stomach and testis. Lower 
expression was also detected in developing skeletal 
muscle, ovary, lung, and adrenal gland. Developing spi- 
nal cord,  superior cervical ganglion (SCG) and dorsal 
root ganglion (DRG) also expressed low levels of 
GDNF mRNA. Two days after nerve transection, 
GDNF mRNA levels increased dramatically in the sci- 
atic nerve. Overall, GDNF mRNA expression was sig- 
nificantly higher in peripheral organs than in neuronal 
tissues. Expression of either GDNF mRNA isoform in 
insect cells resulted in the production of indistinguish- 
able mature GDNF polypeptides. Purified recombinant 
GDNF promoted neurite outgrowth and survival of 
embryonic chick sympathetic neurons. GDNF pro- 
duced robust bundle-like, fasciculated outgrowth from 
chick sympathetic ganglion explants. Although GDNF 
displayed only low activity on survival of newborn rat 
SCG neurons, this protein was found to increase the ex- 
pression of vasoactive intestinal peptide and prepro- 
tachykinin-A mRNAs in cultured SCG neurons. 
GDNF also promoted survival of about half of the neu- 
rons in embryonic chick nodose ganglion and a small 
subpopulation of embryonic sensory neurons in chick 
dorsal root and rat trigeminal ganglia. Embryonic chick 
sympathetic neurons expressed receptors for GDNF 
with Kd 1-5 ×  10 -9 M, as measured by saturation and 
displacement binding assays. Our findings indicate 
GDNF is a new neurotrophic factor for developing pe- 
ripheral neurons and suggest possible non-neuronal 
roles for GDNF in the developing reproductive system. 
T 
HE development and maintenance of the vertebrate 
nervous system requires the activity of a range of 
polypeptides known as neurotrophic factors. These 
molecules have been shown to control the generation, sur- 
vival, differentiation and regeneration of neurons in the pe- 
ripheral and central nervous systems (Barde, 1989; Thoe- 
nen,  1991).  They include  members of the  neurotrophin 
family, including NGF and related molecules (Thoenen, 
1991: Persson  and  Ib~ifiez, 1993),  members  of the  neu- 
rokine family, such as ciliary neurotrophic factor (CNTF),  1 
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1. Abbreviations  used  in  this paper.  BDNF, brain-derived neurotrophic 
factor; BMP, bone morphogenetic proteins; CHAT, choline acetyltrans- 
and  leukemia  inhibitory  factor  (LIF)  (Lin  et  al.,  1989; 
St6ckli  et  al.,  1989; Yamamori  et  al.,  1989)  and  other 
growth  factors  with  neurotrophic  activity  such  as  FGF 
(Knusel et al.,  1990; Cheng and Mattson, 1991; Ip et al., 
1994) and insulin-like  growth factors (IGFs) (Knusel et al., 
1990; Near et al., 1992; Caroni et al., 1994). During devel- 
opment, trophic circuits  formed by these molecules regu- 
ferase;  CGRP,  calcitonin  gene-related  peptide;  CNTF,  ciliary  neu- 
rotrophic factor; DRG, dorsal root ganglion;  FGF, fibroblast growth fac- 
tor: GAPDH,  glyceraldehyde  3-phosphate dehydrogenase; GDNF, glial 
cell  line-derived neurotrophic factor; GITC,  guanidine isothiocyanate; 
IGF, insulin-like growth factor; KLH, keyhole limpet hemocyanin; LIF, 
leukemia inhibitory factor; NT-3, neurotrophin-3; PPTA, preprotachyki- 
nin-A; RPA,  RNAse protection assay;  RT-PCR, reverse transcriptase- 
polymerase chain reaction; SCG, superior cervical  ganglion;  SOM,  so- 
matostatin; VIP, vasoactive intestinal peptide. 
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neurons.  For  example,  sympathetic neuroblasts  can  be 
induced to proliferate with FGF, while requiring neurotro- 
phin-3  (NT-3)  for survival (Birren et al.,  1993; DiCicco- 
Bloom et  al.,  1993).  At later stages,  developing sympa- 
thetic neurons lose responsiveness to NT-3  and become 
dependent on NGF  (Birxen et al.,  1993; Dechant et al., 
1993; DiCicco-Bloom et al., 1993). In addition, CNTF and 
LIF induce neurotransmitter phenotype changes in NGF- 
dependent sympathetic neurons during injury responses 
(Rao et al., 1993; Lewis et al., 1994). Similar multi-trophic 
interactions have also been described for developing sen- 
sory  neurons  (Wright  et  al.,  1992)  and  motorneurons 
(Hughes et al., 1993; Mitsumoto et al., 1994). 
Considerable effort has been devoted to the search for 
novel neurotrophic molecules, among others, factors with 
survival-promoting activities on dopaminergic neurons of 
the substantia nigra, which degenerate during Parkinson's 
disease (O'Malley et al., 1992; Nagata et al., 1993).  One 
such candidate molecule has recently been purified from 
the conditioned medium of rat B49 glial cells on the basis 
of its ability to stimulate dopamine uptake in primary cul- 
tures of ventral midbrain neurons (Lin et al., 1993, 1994). 
This molecule, termed glial cell line-derived neurotrophic 
factor (GDNF), is a disulphide bridge-linked homodimer 
of two  134-residue-long glyc.osylated polypeptide chains 
that are released by proteolytic cleavage from a 211-resi- 
due-long precursor.  GDNF has been shown to promote 
survival of ventral midbrain dopaminergic neurons in cul- 
ture and uptake of dopamine, but not of GABA or seroto- 
nin (Lin et al., 1993), and to increase the number of tyro- 
sine  hydroxylase-immunoreactive neurons in intraocular 
grafts of fetal ventral mesencephalon (Str/Smberg  et al., 
1993). Recently, the ability of GDNF to rescue dopamin- 
ergic neurons has also been confirmed in situ (Tomac et 
al.,  1995; Beck  et  al.,  1995),  supporting the  notion that 
GDNF  may  ameliorate  degeneration  of  dopaminergic 
neurons in patients with Parkinson's disease. The limited 
information available on GDNF mRNA expression sup- 
ports  a  role  for  GDNF  as  a  dopaminotrophic  factor. 
GDNF mRNA has been detected by in situ hybridization 
and  by  reverse  transcriptase-polymerase  chain  reaction 
(RT-PCR) in some brain areas rich in dopaminergic fibers 
and cell bodies, including early postnatal striatum and sub- 
stantia nigra T1 astrocytes (Schaar et al., 1993; Str6mberg 
et al., 1993).  However, low levels of widespread GDNF 
mRNA expression have also been reported, including nor- 
mal  and  kainic  acid-stimulated  hippocampus,  cerebral 
cortex and cerebellum (Humpel et al.,  1994; Springer et 
al.,  1994),  suggesting  GDNF  may  also  have  effects  on 
other  cells  in  addition  to  mesencephalic  dopaminergic 
neurons.  In the present  study, we have investigated the 
expression and function of GDNF outside the central ner- 
vous  system.  Our  findings  indicate  GDNF  is  a  neuro- 
trophic  factor for subpopulations  of peripheral  neurons 
with both target-derived and paracrine modes of action, 
and suggest possible non-neuronal roles for GDNF in the 
developing reproductive system. 
Materials and Methods 
DNA cloning 
A  cDNA fragment containing the coding region of the rat GDNF gene 
(Lin et al., 1993)  was amplified by RT-PCR from rat P1  brain polyA  + 
RNA.  Oligonucleotides  5'GGTCTACGGAGACCGGATCCGAGGT- 
GC3'  (from  nucleotide  1  to  27  of  the  GDNF  cDNA  sequence  as 
published)  and  5'TCTCTGGAGCCAGGGTCAGATACATC3'  (from 
675 to 700) were used as 5' and 3' primers, respectively. The PCR frag- 
ment was subsequently subcloned into pBS-KS  ÷ (Stratagene Corp., La 
Jolla, CA). The identity of the GDNF fragment isolated was confirmed by 
DNA  sequencing.  This  fragment  was  subcloned  into  the  baculovirus 
transfer vector pBacPAK1 (Clontech, Palo Alto, CA) and used to pro- 
duce recombinant baculovirus for GDNF production in insect cells. A 
BamHI-BglI fragment from positions 15 to 383 from the rat GDNF cDNA 
sequence (Lin et al., 1993) was subcloned into pBS-KS  + (Stratagene Corp.). 
The resulting plasmid was linearized and used to generate 32p-labeled  run 
off riboprobes for RNAse protection analysis. This fragment spanned the 
a/13 isoform boundary, and it therefore allowed detection of both GDNF 
mRNA forms in the same sample, cDNA fragments corresponding to rat 
neuropeptide genes were obtained from PI rat brain RNA by RT-PCR 
and subsequently subcloned into pBS-KS  ÷. The CGRP probe consisted of 
a 384-bp fragment encompassing nucleotides 5-388 from the rat CGRP 
sequence (Amara et al., 1982).  The PPTA probe consisted of a 234-bp 
fragment encompassing nucleotides 1 to 234 from the rat PPTA sequence 
(Kawaguchi et al.,  1986).  The vasoactive intestinal peptide (VIP) probe 
consisted of a 218-bp fragment encompassing nucleotides 23-240 from the 
rat VIP sequence (Nishizawa et al., 1985). The somatostatin (SOM) probe 
consisted of a 348-bp fragment encompassing nucleotides 61-408 from the 
rat somatostatin sequence (Goodman et al., 1983). The CCK probe con- 
sisted of a 355-bp fragment encompassing nucleotides 137-491  from the 
rat CCK sequence (Deschenes et al., 1984). 
Antisera 
GDNF antisera were obtained by immunizing rabbits with three different 
synthetic peptides corresponding to amino acid residues 23-40, 51-62, and 
84-97, respectively, from the mature GDNF peptide sequence coupled to 
keyhole  limpet  hemocyanin  (KLH).  Each  peptide  produced  anti-sera 
which recognized GDNF in Western blotting (at a 1:5,000 dilution) and in 
immunoprecipitation. 
Production and Purification of  Recombinant GDNF 
Recombinant baculovirus clones used for GDNF production from insect 
cells were generated using a kit of reagents from Clontech according to 
manufacturer's  instructions.  Low-multiplicity, low-passage virus  stocks 
were used to infect Sf21 cells cultured in serum-free medium (Sf-900-II; 
GIBCO BRL, Gaithersburg, MD) in 1 liter spinner flasks with an agita- 
tion rate of 30 rpm, Conditioned medium was harvested at 72 h  after in- 
fection, adjusted to pH 7.9 with 5 N  NaOH and clarified of debris, The 
medium was then subjected to chromatography on High performance SP- 
Sepharose (Pharmacia, Uppsala, Sweden) in 50 mM phosphate, pH 7,9, 
5 mM EDTA, and eluted with a 0 to 1 M NaC1 linear gradient. Selected 
fractions, identified by Western blotting, were concentrated by ultrafil- 
tration (Amicon Corp., Beverly, MA), pooled, and chromatographed on 
Superdex75 (Pharmacia) in 50 mM phosphate, pH 7.4, 5 mM EDTA, 0.5 M 
NaC1, 10%  acetomtrile. Selected fractions, identified by Western blotting, 
were concentrated by ultrafiltration (Amicon Corp.), pooled and adjusted 
to pH 3.5 with concentrated acetic acid. This sample was then applied to a 
reverse phase C8 HPLC column (Vydac, Hesperia, CA) and eluted with a 
0 to 60% acetonitrile linear gradient in 0.1% TFA. GDNF fractions iden- 
tified by Western blotting, which eluted at 42% acetonitrile, were vacuum 
dried, reconstituted in water, and aliquoted. Silver staining of SDS-PAGE 
gels and NH2-terminal automated Edman degradation sequence analysis 
showed the recombinant GDNF preparation had  a  purity greater than 
90%.  GDNF protein was quantified after silver staining of SDS-PAGE 
gels using standard curves obtained with quantified commercial samples 
of proteins of molecular weight similar to that of GDNF. 
RNA Preparation  and RNAse Protection Assay 
Tissue or ceils were homogenized m guanidine isothiocyanate (GITC) and 
13-mercaptoethanol and RNA was isolated as previously described (Chirg- 
win et al., 1979). For RNA extraction from small samples (~100 mg tissue), 
1/10 vol 2 M sodium acetate, pH 4.0, was added, followed by phenol/chlo- 
roform extraction, and ethanol precipitation. Riboprohes were generated 
from linearized plasmids using T3 or T7 RNA polymerase (Promega Bin- 
tec, Madison, WI) and 3Zp-aCTP. Equal amounts of total RNA (typically 
10 ~g) were analyzed by RNAse protection assay according to manufac- 
turer's  instructions  (Ambion  Inc.,  Austin,  TX).  A  rat  glyceraldehyde 
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Dr.  J.  M.  Blanchard,  Institut  de  Genetique  Moleculaire,  Montpellier, 
France) labeled at low specific activity was added to each sample for sub- 
sequent standardisation.  A 160-nucleotide-long fragment from this probe 
is protected from RNAse digestion.  Samples were then separated in 4% 
polyacrylamide  denaturing  gels and exposed to x-ray films with intensify- 
ing screens at -70°C. Autoradiograms were analyzed with an image anal- 
ysis system (Leica); for quantification,  all sample  signals were standard- 
ised using the signal obtained with the GAPDH probe. To quantitatively 
compare signals for GDNF mRNA in strongly versus weakly expressing 
tissues, autoradiograms  obtained after different exposure times were used 
for quantification.  In some cases, lower amounts  of RNA from highly ex- 
pressing tissues were used for comparison  with samples from low GDNF 
mRNA expressing tissues. 
Bioassays 
For survival assays, chick sympathetic paravertebral chains or rat superior 
cervical ganglia (SCG) were dissected  at different times of development, 
cell dissociates were obtained by trypsin treatment and plated on poly-L- 
ornithine-  and laminin-coated  24-weU plates  at a density of 2,000-10,000 
cells/weU  in DME/F12 (GIBCO BRL) supplemented  with glutamine, pen- 
icillin, streptomycin,  and BSA. Plating efficiency was 60 to 80%. El0 chick 
dorsal root and nodose ganglia, and El6 rat trigeminal  ganglia were also 
dissected  and dissociated  in the same way, except that,  after trypsiniza- 
tion,  cells were pre-plated 2 h in uncoated dishes, where non-neuronal 
cells remain attached, to enrich the preparation in neuronal cells. Survival 
was scored by counting the number of phase-bright  process-bearing  cells 
in a defined area (corresponding  to ~20% of the well) after 48 h in cul- 
ture, and it was expressed as percentage of surviving neurons  from the to- 
tal number of cells initially plated.  Explants  of chick sympathetic  ganglia 
were cultured  in rat tail collagen gels as previously described  (Ebendal, 
1989) and photographed after 48 h in culture. For the analysis of pheno- 
typic  changes  in newborn  rat  SCG neurons,  dissociated  cultures  were 
established  as above in 24-well plates  at a density of 50,000 cells/well in 
defined medium supplemented  with 20 ng/ml NGF. After 24 h, the anti- 
mitotic agent aphidicolin was added to the cultures at 4 p~g/ml, effectively 
eliminating non-neuronal cells. GDNF (100 ng/ml) was added from day 2, 
Figure 1.  (A) Schematic representation of the predicted GDNFa 
and GDNF~ mRNA isoforms. Hatched bars indicate coding se- 
quence, flanked by start (ATG) and termination (TGA) codons. 
The riboprobe  used  in RNAse protection analyses,  transcribed 
from a  BamHI-BglI cDNA fragment, is indicated in the top of 
the figure; fragment sizes are in nucleotides. (B) RNAse protec- 
tion analysis of postnatal day 1 (P1) kidney RNA and RNA from 
a fibroblast cell line stably transfected with the GDNF[3 mRNA 
isoform (F3A-GDNF~) and from a mock-transfected control line 
(F3A-MT). A  full-length probe fragment of 369 nucleotides, not 
shown in the figure, corresponding to the GDNFct mRNA iso- 
form, was protected by P1  kidney RNA but not by the cell line 
RNA. Apart from this band, both samples protected fragments of 
sizes  corresponding  to  those  predicted  by  the  structure  of the 
GDNF~  cDNA clone  (see A), confirming that  GDNFI3  corre- 
sponds  to an  authentic GDNF mRNA isoform. No bands  were 
detected in mock-transfected cell line RNA. 
Figure 2.  (A) Reverse-phase HPLC purification of recombinant 
GDNF.  A  concentrated  pool of fractions from the  Superdex75 
size exclusion chromatography column showing immunoreactiv- 
ity with anti GDNF peptide antisera was applied to a C8 column 
and  eluted  with  an  acetonitrile  gradient.  The  absorbance  was 
monitored at 214 nm. Protein immunoreactve with GDNF anti- 
peptide antibodies and displaying biological activity was present 
in the major peak of the chromatogram eluting at 42%  acetoni- 
trile. (B) Glycanase treatment of insect cell--derived recombinant 
GDNF.  Insect cell--derived GDNF runs  as a  doublet of 20  and 
23K,  respectively, in  silver stained  SDS-PAGE  gels  (-)  (left). 
Glycanase treatment (+) results in a relatively higher proportion 
of the 20 K species and in the appearance of a 16K species, pre- 
sumably representing the unglycosylated mature GDNF peptide. 
Molecular weights  are  indicated  in  kilo Daltons.  glyc indicates 
the migration of the glycanase enzyme (mol wt = 52K). Western 
blotting analysis of a SDS-PAGE gel similar to that shown in A 
using a cocktail of three anti-GDNF peptide antisera (right).  All 
bands  are recognized by the GDNF antibodies, confirming they 
all correspond to GDNF. 
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distribution  of  GDNF 
mRNA  (ct  isoform)  expres- 
sion in rat peripheral organs, 
peripheral  ganglia,  and  cell 
lines. The upper panels show 
autoradiograms  of  RNAse 
protection assays (~10 }xg of 
total  RNA  per  lane),  the 
lower panels show the quan- 
tification  of  the  level  of 
GDNF mRNA in each sam- 
ple  relative  to  the  level  of 
GDNF mRNA in P1  kidney, 
and  standardised  to  the  sig- 
nal obtained with a  low spe- 
cific  activity  GAPDH  ribo- 
probe  added  simultaneously 
with  the  GDNF  probe  to 
each  RNA  sample.  Autora- 
diograms  of  different  expo- 
sure  times  and  from  several 
different  experiments  were 
used  for  GDNF  mRNA 
quantification.  (A)  GDNF 
mRNA  distribution  at  the 
time  of  maximal  expression 
in rat peripheral tissues. (B) Expression of GDNF mRNA in embryonic spinal cord, newborn dorsal root ganglia (DRG), superior cer- 
vical ganglia (SCG), and postnatal striatum. (C) Expression of GDNF mRNA in the astroglioma line C6, in the Sertoli cell line TM4, in 
the pheochromocytoma line PC12 and in PC12 cells after 24 h treatment with NGF. 
and cultures were harvested  by GITC lysis at day 6. Approximately 10 p~g 
of total RNA were obtained from six wells using the acid-phenol method 
(see above). 5 }xg RNA was used for analysis of neuropeptide and choline 
acetyltransferase  (CHAT)  mRNAs  by  RNAse protection  assay  as  de- 
scribed above. 
Binding Assays 
Purified  recombinant  GDNF was labeled with 125I by the chloramine-T 
method  to  an  average  specific  activity  of 5  x  10  7 cpm/lJ,  g.  Iodinated 
GDNF retained more than 90% of its biological activity as assessed in the 
sympathetic  ganglion explant  bioassay. Chick sympathetic  neurons  were 
isolated from El0 paravertebral sympathetic chains by trypsinization  and 
plated for 3 h to allow receptor re-expression. The plating procedure also 
effectively enriched  the preparation in neuronal  cells, since these do not 
adhere  to the plastic  surface.  Steady  state  saturation  binding  was per- 
formed in triplicate  wells with 350,000 neurons/ml  and serial dilutions  of 
iodinated  GDNF in Dulbecco-phosphate  buffer saline supplemented  with 
1 mg/ml BSA and 1 mg/ml glucose. Competition binding assays were per- 
formed at 4°C using 0.3 ×  10  9 M iodinated factor and serial dilutions of 
unlabeled  GDNF or NGF. All components  were added at the same time 
and  the  cells  were  collected  by  centrifugation  after  equilibrium  was 
reached  (90-120-min  incubation).  Cell  pellets were  then counted  in  a 
gamma counter.  Nonspecific binding was measured  in a parallel  incuba- 
tion to which 300- to 500-fold molar excess of unlabeled  purified  GDNF 
was added. All results were corrected for this nonspecific binding. 
Results 
Alternative Splicing Generates a Shorter GDNF 
Precursor Protein 
A  GDNF  cDNA  was  cloned by RT-PCR  from postnatal 
day 1 (P1) rat brain mRNA  using primers flanking the ini- 
tiation  and  stop  codons,  respectively,  of  the  reported 
GDNF  gene open reading frame (Lin et al., 1993). In addi- 
Figure 4.  Expression of GDNF 
mRNA in developing rat kid- 
ney (A), lung (B), and gastroc- 
nemius  muscle  (C).  El3  and 
El6 samples in  C correspond 
to limb bud RNA. The upper 
panels  show  autoradiograms 
of  RNAse  protection  assays, 
the  lower  panels  show  the 
quantification  of the  level of 
GDNF mRNA in each sample 
relative to the level of GDNF 
mRNA in P1 kidney and stan- 
dardised to the signal obtained 
with  a  GAPDH  riboprobe 
added  simultaneously  with 
the  GDNF  probe  to  each 
RNA sample. 
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(A) and ovary (B). The upper panel in A shows an autoradiogram 
of a RNAse protection assay. The lower panels show the quantifi- 
cation  of the level of GDNF mRNA in each sample relative to 
the level of GDNF mRNA in P1 kidney and standardised  to the 
signal obtained with a GAPDH riboprobe added simultaneously 
with the GDNF probe to each RNA sample. 
tion to the previously described GDNF cDNA, a  shorter 
cDNA was also specifically amplified.  Sequence  analysis 
revealed this shorter fragment corresponded to a  GDNF 
cDNA with a 78 nucleotide deletion in the prepro region 
of the  coding sequence  (Fig.  1 A).  Comparison with the 
longer GDNF cDNA, termed GDNFet, indicated that the 
shorter form, termed GDNF13, resulted from the use of an 
alternative  donor  splice  site  during  GDNF  mRNA  pro- 
cessing. To verify that the amplified GDNF13 cDNA corre- 
sponded to a bone fide transcript, RNAse protection anal- 
ysis was performed using a  riboprobe spanning the splice 
junction of GDNFet mRNA (Fig. 1 A). The pattern of pro- 
tected  bands in  a  GDNF mRNA expressing tissue  (post 
natal day 1 [P1] kidney, see below) was compared to that 
in a  fibroblast cell line which had been stably transfected 
with  a  GDNF13  cDNA  (F3A-GDNF13).  As  expected,  a 
fragment  of 369  nucleotides,  corresponding  to  the  full- 
Figure 6.  Time course of the expression of GDNF mRNA in the 
rat sciatic nerve after nerve transection.  The upper panel shows 
an autoradiogram of a RNAse protection assay. Yeast tRNA was 
used  as  negative control  (tRNA).  The  lower panel shows  the 
quantification  of the level of GDNF mRNA in each sample rela- 
tive to the level of GDNF mRNA in P1 kidney and standardised 
to the signal obtained with a GAPDH riboprobe added simulta- 
neously with the GDNF probe to each RNA sample. Data are ex- 
pressed as mean -  SD of two independent experiments. 
length probe (Fig. 1 A), was protected by P1 kidney RNA 
but not by the cell line RNA  (not shown, see below). In 
addition, two other major fragments of 183 and 108 nucle- 
otides, corresponding to RNAse cleavage of the probe at 
the  GDNF splice junction  and  at a  second site 78 nucle- 
otides  upstream,  respectively,  were  protected  by  both 
RNA  samples  (Fig.  1  B),  indicating  that  the  GDNF13 
cDNA  corresponds  to  an  authentic  GDNF  mRNA  iso- 
form. No protected fragments were seen using RNA from 
the parental untransfected cell line (Fig. 1 B). 
In addition, the deletion  (26 amino acids) also changes 
Gly25 into Ala. Although the alternative splicing does not 
change the reading frame of translation, it could conceiv- 
ably  influence  the  processing  of  the  GDNF  precursor. 
GDNFtx  and  13  cDNAs  were  expressed  in  baculovirus- 
infected insect cells and recombinant protein was purified 
to homogeneity. Insect cell-derived GDNF eluted at 42% 
acetonitrile in reverse phase HPLC (Fig. 2 A). NH2-termi- 
nal amino acid sequencing for 11 cycles confirmed the pu- 
rity and the predicted sequence of mature GDNF; contam- 
inants consisted of GDNF molecules lacking the first two 
amino acid residues from the NH2 terminus. Both GDNFc~ 
and  13  protein  isoforms  gave  identical  NH2-terminal  se- 
quences. GDNF~x runs as a doublet of 20 and 23K, respec- 
tively, in polyacrylamide gels under denaturing conditions 
(Fig. 2 B). Treatment with N-glycanase resulted in the ap- 
pearance  of a  polypeptide band  of 16K,  indicating  that, 
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Figure 7.  Survival of newborn rat SCG neurons with GDNF. Dis- 
sociated  cultures  of rat P1 SCG neurons were grown for 48 h in 
the presence of increasing  concentrations  of purified recombi- 
nant GDNF (11) or NGF (E3). Results  are expressed as the per- 
centage of the total number of neurons plated that survived after 
48 h in culture (triplicate determinations) +__ SD. The inset details 
the response to GDNF. *, P < 0.001 versus no factor added. 
like  native  GDNF  (Lin  et  al.,  1993),  insect  cell--derived 
GDNF is N-glycosylated (Fig. 2 B). The sample was en- 
riched  in the 20  and  16K bands  after N-glycanase treat- 
ment, suggesting that the 20K species is a glycosylated in- 
termediate. Heterogeneity in the carbohydrate content of 
GDNF has recently been detected in preparations of na- 
tive GDNF (Lin et al., 1994). All three species were recog- 
nized by anti-GDNF peptide antiserum in Western blots, 
confirming they all corresponded to GDNF (Fig. 2 B). No 
differences in mobility were observed between the mature 
forms  of  GDNF  produced  using  either  the  a  or  the 
cDNA (data not shown). 
Expression of GDNF mRNA in Peripheral tissues 
The limited information available indicates GDNF mRNA 
is expressed at very low levels (Schaar et al., 1993; Strrm- 
berg et al., 1993; Springer et al., 1994). We studied the ex- 
pression of non-amplified GDNF mRNA in the develop- 
ing rat using a  sensitive RNAse protection assay (RPA). 
Fig. 3 A  shows an overview of the distribution of GDNFct 
mRNA at the time of maximal expression in different pe- 
ripheral  tissues.  GDNFot  mRNA  was  found  to  be  ex- 
pressed in  several tissues  of the  developing rat,  notably 
postnatal testis and  kidney,  and embryonic whisker pad, 
stomach, and skin  (Fig. 3 A). Expression in whisker pad 
was maximal between embryonic day 13  (El3)  and  El6 
and subsequently declined towards E18 (data not shown). 
Lower levels were also seen in embryonic muscle and ad- 
renal gland and postnatal lung, liver, and ovary (Fig. 3 A). 
Very low levels of GDNFct mRNA could be detected in 
postnatal heart, spleen, thymus and thyroid, pituitary, and 
salivary glands (Fig. 3 A). Low levels of GDNFct mRNA 
were  also  found  in  early  postnatal  dorsal  root  ganglia 
(DRG) and SCG (Fig. 3 B), but could not be detected in 
the  adult  ganglia  (not shown).  GDNFa mRNA was also 
Figure 8.  GDNF regulates the phenotype of newborn rat SCG 
neurons.  (A)  Autoradiograms of RNAse  protection  assays  of 
RNA samples from cultures of P1 rat SCG neurons grown for 4 d 
in the absence (-) or presence (+) of 100 ng/ml recombinant 
GDNF. (B) Quantification  of neuropeptide mRNA levels in cul- 
tures of rat SCG neurons treated with 100 ng/ml GDNF relative 
to the levels in untreated cultures.  The values  have been stan- 
dardized to the signal obtained with a GAPDH riboprobe run si- 
multaneously  with the neuropeptide probes. Data are expressed 
as mean +- SD of three independent experiments. 
found to be expressed in embryonic spinal cord at levels 
comparable to those detected in P10 striatum (Fig. 3 B), 
the region that shows the maximal expression of GDNFot 
mRNA in the rat brain (Trupp, M., and C. F. Ib~fiez, un- 
published results).  In general, the expression of GDNF~ 
mRNA paralleled that of the a  isoform (data not shown). 
Overall, the expre.ssion of GDNF mRNA was significantly 
higher in peripheral organs compared to neuronal tissues. 
Several cell lines were found to express GDNF mRNA, in- 
cluding the  astrocytoma line  C6  and the  Sertoli cell line 
TM4 (Fig. 3 C). Expression of GDNF mRNA in TM4 ceils 
suggests Sertoli cells may be the source of GDNF mRNA 
in the testis. The rat pheochromocytoma cell line PC12 did 
not show detectable GDNF mRNA expression, but it was 
found  to  express  GDNF mRNA  after  a  24  h  treatment 
with NGF (Fig. 3  C), which causes differentiation into  a 
sympathetic neuron-like cell type. 
GDNF  mRNA  was  highly  expressed  throughout  the 
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oping  chick  paravertebral 
sympathetic  neurons  with 
GDNF.  (.4) Dissociated  cul- 
tures  of  El0  chick  sympa- 
thetic  neurons  were  grown 
for 48 h in the presence of in- 
creasing  concentrations  of 
purified  NGF  (rT) or  puri- 
fied recombinant GDNF (11). 
Results  are expressed as the 
percentage of the total num- 
ber  of  neurons  plated  that 
survived after 48 h in culture 
(triplicate  determinations)  _+ 
SD. (B) Survival of E8, El2, 
and  El7  chick  sympathetic 
neurons in the presence of 20 
ng/ml NGF (solid bars), GD- 
NFct (hatched  bars), or GD- 
NFft  (shaded  bars).  Results 
are expressed as the percent- 
age  of the  total  number  of 
neurons plated that survived 
after 48 h  in  culture  (tripli- 
cate  determinations)  +  SD. 
*, P < 0.001 compared to the 
cultures grown in the absence 
of  factors.  (C)  Bright  field 
micrograph  of  El0  chick 
sympathetic  neurons  grow- 
ing in the presence of 10 ng/ 
ml NGF. (D) Bright field mi- 
crograph of E12  chick  sym- 
pathetic neurons  growing  in 
the presence of 10 ng/ml GD- 
NFc~. (E) Bright  field micro- 
graph  of  E12  chick  sympa- 
thetic  neurons  growing  in 
the  absence  of  trophic  fac- 
tors. 
embryonic development of kidney  (from El3  onwards), 
with  decreasing  levels after birth  (Fig.  4 A).  No  GDNF 
mRNA could be detected in adult kidney (not shown). In 
contrast, GDNF mRNA expression in lung increased dur- 
ing development and showed a biphasic profile, with a first 
peak around birth and a second peak at the third post na- 
tal week (Fig. 4 B). Levels of GDNF mRNA decreased in 
developing gastrocnemius muscle from El9 to P23, maxi- 
mal levels were seen in El3 and El6 litnb bud (Fig. 4 C). 
No GDNF mRNA could be detected in adult muscle (not 
shown). GDNF mRNA expression in testis increased dur- 
ing  development  and  peaked  at  P7  (Fig.  4  A).  Subse- 
quently,  the  level  of GDNF  mRNA  in  testis  decreased 
during the  second and third post natal weeks and it was 
lowest in adult testis (Fig. 5 A). GDNF mRNA expression 
in  ovary increased  during  early  postnatal  development, 
peaked at three weeks and subsequently decreased down 
to very low levels in the adult (Fig. 5 B). 
GDNF mRNA levels were very low in intact rat sciatic 
nerve (Fig. 6). However, a dramatic increase was observed 
after nerve transection  (Fig. 6).  GDNF mRNA levels (a 
isoform) peaked 2 d  after the lesion and decreased there- 
after (Fig. 6).  14 d  after transection, the latest time point 
tested, GDNF mRNA was still highly expressed in the sci- 
atic nerve. 
Trophic Activities of GDNF in Developing Peripheral 
Mammalian and Avian Neurons 
The pattern of expression of GDNF mRNAs in peripheral 
tissues suggested that GDNF might have biological effects 
on peripheral neurons. We investigated the biological ac- 
tivities  of  GDNF  in  sympathetic  neurons  from  the  rat 
SCG. GDNF (produced from the et cDNA isoforrn) dis- 
played low but significant activity on survival of P1  SCG 
neurons in culture (Fig. 7). At 100 ng/ml, GDNF rescued 
survival of about 10% of the P1 SCG neurons;  half-maxi- 
mal response was seen at 4-5 ng/ml (Fig. 7). NGF, in con- 
trast,  supported  the  majority  of  the  SCG  neurons,  and 
half-maximal response was seen at 0.3-0.4 ng/ml (Fig. 7). 
GDNF also displayed low but measurable activity on El6 
SCG neurons  (data  not  shown)  at levels comparable to 
NGF, which, in contrast to P1 SCG, supports only a small 
fraction  of  neurons  in  E16  SCG  (Birren  et  al.,  1993; 
DiCicco-Bloom et al., 1993). 
A  number  of trophic  factors and  cytokines, including 
Trupp et al. Peripheral  Expression  and Activities of GDNF  143 Figure 10.  Neurite outgrowth promoted by GDNF and NGF in explanted El0 chick sympathetic paravertebral ganglia. Explants were 
cultured for 48 h in the presence of purified GDNF (A, 3 ng/ml; B, 10 ng/ml; C, 30 ng/ml; D, 100 ng/ml; E, 300 ng/ml) or purified NGF (F, 
0.1 ng/ml; G, 1 ng/ml; H, 10 ng/ml). An explant cultured in the absence of trophic factors is shown in L Arrows in A, B, and D show bun- 
dle-like fibers emanating from GDNF-treated explants. 
members of the TGF13 superfamily, have been shown to 
influence  the  complement  of  neuropeptides  and  neu- 
rotransmitters expressed by newborn rat SCG neurons in 
culture (Fann and Patterson, 1994). Despite its low effects 
on survival of rat P1 SCG neurons, GDNF was found to 
regulate the phenotype of these neurons in vitro. Cultures 
of P1  rat  SCG  neurons  were  grown in  the  presence  of 
NGF as a survival factor and aphidicolin as an antimitotic 
agent.  The  expression of mRNAs  coding for calcitonin 
gene-related peptide  (CGRP),  CHAT, preprotachykinin- 
A  (PPTA), vasoactive intestinal peptide (VIP), and SOM 
were analyzed by RPA on RNA extracted from cultures 
grown for 4  d  in  the  presence or absence  of 100  ng/ml 
GDNF.  GDNF  treatment  upregulated  PPTA  and  VIP 
mRNA levels (2- and 3.3-fold, respectively) (Fig. 8). No 
significant change was seen in the levels of CGRP, SOM 
(Fig. 8), or ChAT (data not shown) mRNAs. 
In contrast to the effects on rat SCG neurons, GDNF 
promoted robust survival of El0 chick paravertebral sym- 
pathetic neurons (Fig. 9 A). Although GDNF was able to 
rescue the majority of these neurons, it was somewhat less 
potent than NGF, with an ECs0 at 2ng/ml, compared to 0.8 
ng/ml for NGF (Fig. 9 A). GDNF protein produced from 
the GDNF[3 cDNA displayed identical potency and effi- 
cacy in El0 chick sympathetic neurons as that produced 
from the  GDNFa  eDNA  (data  not  shown).  GDNF  re- 
sponsiveness  increased  during  embryonic  chick  sympa- 
thetic development from E8 to El2 (Fig. 9 B). Again, no 
difference could be observed between proteins produced 
from either the et or 13 GDNF eDNA isoforms (Fig. 9 B). 
Responsiveness to NGF also increased between E8 and 
E12 (Fig. 9 B), in agreement with previous observations 
(Dechant et al.,  1993).  Cultures of El0 chick sympathetic 
neurons grown in the presence of 10 ng/ml GDNF or NGF 
had similar morphological appearance; like NGF, GDNF 
induced extensive neurite outgrowth and increase in cell 
body size (compare Fig.  9,  C, D,  and E).  The ability of 
GDNF to induce neurite outgrowth was evaluated in ex- 
plants  of  El0  chick  paravertebral  sympathetic  chains. 
GDNF  elicited  a  characteristic  bundle-like,  fasciculated 
outgrowth from sympathetic explants  (Fig.  10, A  to  E). 
NGF,  in  contrast,  produced thin, long neurites, that  re- 
sulted in a dense halo with increasing concentrations (Fig. 
10, F-H). As previously observed with NGF, a saturation 
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oping  sensory neurons  with 
GDNF. (A) Dissociated  cul- 
tures of El0 chick dorsal root 
ganglion  (DRG)  neurons 
were grown  for 48 hr in the 
presence  of increasing  con- 
centrations  of  purified  re- 
combinant  GDNF  (11)  or 
NGF  ([]).  Results  are  ex- 
pressed as the percentage of 
the total number of neurons 
plated  that  survived  after 
48 h in culture  (triplicate  de- 
terminations) ±  SD. The in- 
set  details  the  response  to 
GDNF.  *, P  <  0.001 versus 
no factor added.  (B) Dissoci- 
ated  cultures  of  El0  chick 
nodose  ganglion  neurons 
were grown  for 48  h  in  the 
presence  of  increasing  con- 
centrations  of  purified  re- 
combinant  GDNF  (11)  or 
BDNF  ([2).  Results  are  ex- 
pressed as the percentage of 
the total number of neurons 
plated  that  survived  after 
48 h in culture  (triplicate  de- 
terminations)  ± SD. (C) Dissociated cultures of El6 rat trigeminal ganglion neurons were grown for 48 h in the absence (MEDIUM) or 
presence of 10 ng/ml GDNF, 100 ng/ml GDNF, or 10 ng/ml NGF. Results are expressed as the percentage of the total number of neu- 
rons plated that survived after 48 h in culture (triplicate determinations) +- SD.*, P < 0.01 versus no factor added. 
in the response to GDNF was seen at high concentrations, 
resulting  in  an  inverted  U-shaped  dose-response  curve. 
GDNF-induced  neurite  outgrowth  was  observed from 3 
ng/ml, peaked at 100 ng/ml and showed saturation above 
300 ng/ml (Fig. 10, A-E). Outgrowth response to NGF was 
observed from 0.1 ng/ml, peaked at 3 ng/ml and saturated 
above  10  ng/ml  (Fig.  10,  F-H).  No  outgrowth  was  ob- 
served in controls grown in the absence of factor (Fig. 10/). 
GDNF promoted survival of a small subpopulation (4- 
5%)  of neurons from El0  chick DRG  (Fig.  11 A). Half 
maximal response, however, was obtained at levels com- 
parable  to  those  of  NGF  (0.3--0.4  ng/ml).  In  contrast, 
GDNF promoted robust survival of El0 chick nodose gan- 
glion neurons, at levels comparable, or superior, to brain- 
derived  neurotrophic  factor  (BDNF)  (Fig.  11  B).  Half 
maximal response was at 1-2 ng/ml for GDNF, compared 
to  0.3  ng/ml for BDNF.  A  small proportion  of neurons 
from El6 rat trigeminal ganglia (~5%) also responded to 
GDNF (Fig. 11 C). 
GDNF Receptors in Embryonic Chick 
Sympathetic Neurons 
GDNF receptors in embryonic chick sympathetic neurons 
were examined in saturation and displacement binding as- 
says. GDNF iodinated  with chloramine T  retained  more 
than 90% of its biological activity as assessed in the sym- 
pathetic ganglion explant bioassay. 125I-GDNF binding to 
embryonic sympathetic neurons  showed  saturation  (Fig. 
12  A)  with  half maximal saturation  at  1  x  10 -9 M  and 
75,700  binding  sites/cell  (as  calculated  from the  BMAX). 
Unlabeled GDNF displaced iodinated GDNF from bind- 
ing sites in sympathetic neurons in a dose-dependent man- 
ner (Fig. 12 B); the ICs0was at 5  ×  10-9M. NGF failed to 
displace iodinated GDNF from sympathetic neurons (Fig. 
12 B). 
Discussion 
It has been proposed that GDNF is a  highly specific and 
potent  neurotrophic  agent  for  dopaminergic  neurons  of 
the ventral mesencephalon (Lin et al., 1993; Tomac et al., 
1995; Beck et al., 1995), which degenerate in patients with 
Parkinson's disease. In this study we investigated the pro- 
file of expression and biological activities of this protein in 
peripheral  tissues  and  neurons  of  the  developing  rat. 
GDNF mRNA was expressed in various peripheral tissues 
as two isoforms termed et and [3, respectively. These two 
mRNAs are generated by alternative splicing, resulting in 
a 26-amino acid residue deletion in the middle of the pre- 
pro region of the shorter (GDNFI3) form. We have shown 
that the deletion, however, does not interfere with the site 
of proteolytic cleavage that  releases  the  mature  GDNF 
form since  both  GDNF protein  isoforms  have  identical 
NH2-terminal sequences. Both protein isoforms appear to 
be glycosylated to the same extent in Sf21  insect cells, as 
judged by polyacrylamide gel electrophoresis and, further- 
more, display indistinguishable biological activity in a sym- 
pathetic survival bioassay, suggesting that identical mature 
GDNF proteins are produced from the  two mRNA iso- 
forms. The significance of the existence of two GDNF iso- 
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Figure 12.  GDNF receptors in embryonic chick sympathetic neu- 
rons.  (A) Saturation  steady-state  binding of 125I-GDNF to El0 
embryonic  chick  sympathetic  neurons.  Data  are expressed  as 
mean --+ SD of triplicate determinations.  (B) Steady-state binding 
of x251-GDNF to El0 embryonic chick sympathetic neurons com- 
peted with increasing concentrations  of unlabeled GDNF (m) or 
unlabeled NGF ([]). Data are expressed as mean ~ SD of tripli- 
cate determinations. 
forms is at present not understood but could be related to 
differences in mRNA or prepropeptide processing or sta- 
bility, which may only be manifested in cells that normally 
express GDNF. 
GDNF mRNA was found to be expressed in some tis- 
sues  receiving sympathetic innervation,  such  as  kidney, 
stomach, lung and salivary gland. The predominantly post- 
natal expression in the latter two organs suggest GDNF 
may be serving a maintenance role for the sympathetic in- 
nervation  of  these  tissues,  as  sympathetic  neurons  are 
known to require continuous trophic support. The earlier 
expression of GDNF mRNA in developing kidney may in- 
dicate a  role for GDNF during the establishment of the 
sympathetic innervation of this tissue. It may also be possi- 
ble that GDNF synthesis in kidney is unrelated to sympa- 
thetic innervation and has an exocrine function, like that 
of the  bone  morphogenetic proteins  (BMPs),  which,  as 
GDNF,  are  also TGFI3 superfamily members  expressed 
during kidney embryonic development (Ozkaynak et al., 
1991, 1992). 
Although  not  directly innervated  by  the  sympathetic 
trunk, the reproductive organs receive sympathetic inner- 
vation from the  inferior mesenteric ganglion.  However, 
the temporally restricted, predominantly postnatal pattern 
of GDNF mRNA expression in testis and ovary suggests 
GDNF may play a non-neuronal role in these tissues. In 
the rat testis, postmeiotic cells appear at about 25 d of age, 
whereas somatic cells, including Sertoli cells, make up the 
bulk of the seminiferous epithelium during the early post- 
natal development of the testis (Bellve, 1979). The tempo- 
ral expression of GDNF mRNA  in testis correlates with 
the  expansion  of the  Sertoli cell population,  which  be- 
comes diluted at later stages by the increased number of 
germ cells.  GDNF mRNA  was  expressed by the  Sertoli 
cell line TM4, suggesting that GDNF may be produced by 
developing Sertoli cells in vivo. GDNF in the testis could 
have effects on the early stages of spermatogenesis, per- 
haps in the proliferation or maturation of spermatogonia, 
or on Leydig cells. It is interesting to note in this respect 
that TGFI3 has been shown to be expressed by Sertoli cells 
and it appears to affect the maturation of Leydig cells and 
the production of extracellular matrix components in the 
seminiferous epithelium (Benahmed et al., 1989). 
The expression of GDNF mRNA in embryonic whisker 
pad and skin, together with the effects of GDNF on the 
survival of a small subpopulation of developing trigeminal 
neurons suggest this protein may be a physiological factor 
for sensory fibers innervating  skin  and  hair  follicles. A 
complex and partially overlapping pattern of trophic fac- 
tor expression has been reported in the rat whisker pad 
(Ib~ifiez et al., 1993), suggesting these molecules may act in 
concert to orchestrate the innervation of different struc- 
tures  by different subpopulations  of trigeminal ganglion 
neurons. Interestingly, robust activity was seen on survival 
of embryonic chick nodose ganglion neurons, suggesting 
that other populations of placode-derived sensory neurons 
may  also  respond  to  the  survival-promoting  effects  of 
GDNF. 
The presence of GDNF mRNA in limb bud and in de- 
veloping skeletal muscle may also indicate a target-derived 
action on sensory neurons, as GDNF was able to rescue 
the survival of a small subpopulation of embryonic chick 
DRG neurons in culture. Interestingly, the sensory neu- 
rons rescued by GDNF appeared to be of large diameter, 
presumably proprioceptive neurons (C. F. Ib~ifiez, unpub- 
lished results), although confirmation of this observation 
must await quantitative analysis. After submission of this 
paper, a study reported on the ability of newborn rat DRG 
neurons to retrogradely transport iodinated GDNF (Yan 
et al., 1995), suggesting that rat DRG sensory neurons may 
also be responsive to the factor. Another possible function 
for GDNF produced in the muscle has been suggested by 
recent reports on the effects of GDNF on the survival of 
spinal  cord and facial motor neurons  (Henderson et al, 
1994; Yah et al., 1995; Oppenheim et al., 1995). In this con- 
text, it is worth noting the dramatic upregulation of the 
levels of GDNF mRNA in the rat sciatic nerve after nerve 
transection, suggesting that GDNF may be a physiological 
factor for sensory and motor nerve repair. This lesion has 
previously been shown to induce the expression of other 
motor neuron trophic factors such as BDNF (Funakoshi et 
al., 1993).  In contrast to BDNF, however, GDNF mRNA 
upregulation occurs with a faster time course; after a peak 
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nerve decreased and appeared to stabilize at intermediate 
levels.  The  recent  demonstration  by  Henderson  et  al. 
(1995)  of GDNF mRNA expression in cultured newborn 
rat Schwann ceils suggests these cells may be the source of 
GDNF  mRNA  detected  after  transection  of the  sciatic 
nerve in the present study. 
The demonstration of trophic effects of GDNF on de- 
veloping sympathetic neurons adds this protein to the list 
of factors with trophic activities on these cells (Levi-Mon- 
talcini  and  Angeletti,  1968;  Manthorpe  et  al.,  1985;  Un- 
siker  et  al.,  1987).  Although  somewhat less potent  than 
NGF,  GDNF  promoted  survival  of  as  many El0  chick 
sympathetic neurons  as NGF, with ECs0 in the  order  of 
2 ng/ml. Neurite outgrowth stimulated by GDNF in sym- 
pathetic ganglion explants displayed characteristic bundles 
of relatively short, fasciculated fibers emanating from the 
explant, which contrasted with the thin and dense neurite 
halo observed in response to NGF. No morphological dif- 
ferences in the response to the two factors were, however, 
apparent  in  dissociated  cultures.  The  different morphol- 
ogy of the outgrowth stimulated in explants could be due 
to differences in the sets of cell adhesion molecules or cy- 
toskeletal elements induced by each factor. The fact that 
rat GDNF displayed substantial activity on chick neurons 
suggests the existence of a putative GDNF homologue in 
chicken with close structural similarities to the mammalian 
protein. After submission of this paper, Oppenheim et al. 
(1995) reported on the ability of exogenous GDNF to in- 
crease the  number of sympathetic neurons  in  avian em- 
bryos,  suggesting  GDNF  may  regulate  sympathetic cell 
number  in  vivo.  Interestingly,  however,  our  results  re- 
vealed a difference in the response to GDNF between de- 
veloping chick and rat sympathetic neurons.  Responsive- 
ness to GDNF increased during embryonic development 
of chick paravertebral sympathetic neurons, but it was low 
in newborn rat SCG neurons. This could be due to differ- 
ences in the developmental programs of sympathetic neu- 
rons  in  the  two  species  or  to  differences  in  the  trophic 
requirements  of  paravertebral  versus  superior  cervical 
sympathetic neurons. Differences in responsiveness to fac- 
tors  have  previously  been  observed  between  rat  and 
chicken sympathetic neurons (Smith et al., 1993). Despite 
its low effects on neuronal  survival of rat SCG neurons, 
GDNF was able to regulate the phenotype of these cells in 
culture. Given the low numbers of neurons responding to 
the survival-promoting effects of GDNF, further analysis 
will be required to determine whether the elevated levels 
of  neuropeptide  mRNA  expression  induced  by  GDNF 
correspond to a  very high increase in  a  small number of 
cells  or  to  a  moderate homogenous  increase.  In this  re- 
spect, it is worth noting that members of the TGF[~ super- 
family have been shown to interact with multiple receptors 
with intrinsic serine-threonine kinase activity (Attisano et 
al.,  1994;  Kingsley,  1994).  TGF~, for example, has  been 
shown  to  bind  and  promote  distinct  biological  effects 
through  a  type II serine-threonine  kinase receptor com- 
bined with either one out of three different type I recep- 
tors  (C~trcamo  et  al.,  1994).  Thus,  it  is  conceivable  that 
GDNF may mediate survival and phenotypic changes in 
sympathetic neurons via related, yet distinct, subsets of re- 
ceptors, which could be present in partially overlapping, 
yet  different,  subpopulations  of  sympathetic  neurons. 
Some of these receptor subunits may even be shared with 
other TGFI3 supeffamily members. In a recent study, Fann 
and Patterson (1994)  reported the results of a  systematic 
survey of neuropoietic  cytokines  and  growth  factors for 
effects on  the  phenotype  of cultured  newborn  rat  SCG 
neurons. Activin A  (a member of the TGF[3 supeffamily) 
induced a  pattern of neuropeptide and neurotransmitter- 
synthesizing enzyme mRNAs that was distinct  from that 
induced by neuropoietic cytokines such as LIF and CNTF. 
In  particular,  activin  A  upregulated  the  expression  of 
SOM  and  CGRP  mRNAs,  but,  as  opposed to  LIF and 
CNTF, it had no effects on VIP and PPTA mRNAs (Fann 
and  Patterson,  1994).  GDNF  appears to  share  with LIF 
and  CNTF  the  ability  to  upregulate  mRNAs  for PPTA 
and  VIP but,  in  contrast  to  the  two  neurokines,  GDNF 
does  not  affect  the  levels  of  ChAT  or  SOM  mRNAs. 
Moreover, unlike activin A, LIF, CNTF, and GDNF have 
no effect on the level of CGRP mRNA. Thus, these find- 
ings place GDNF in a distinct category among modulators 
of the sympathetic neuronal phenotype. 
In summary, we have found widespread  expression of 
GDNF  mRNA  in  developing  peripheral  tissues  and 
trophic activities of GDNF protein on populations of de- 
veloping  mammalian  and  avian  peripheral  neurons.  In 
some cases, the pattern of GDNF mRNA expression cor- 
related  with  sympathetic,  sensory or  motor innervation, 
suggesting  a  physiological  trophic  role  for  GDNF  pro- 
duced  in  these  tissues.  In addition,  the  endogenous  pro- 
duction of GDNF mRNA in newborn DRG, SCG and em- 
bryonic spinal cord may indicate a paracrine or autocrine 
mode of action in these tissues. The expression of GDNF 
mRNA in reproductive organs did not correlate with in- 
nervation  and  could  indicate  a  non-neuronal  role  for 
GDNF in these  organs, perhaps in the  differentiation  of 
early germ cell precursors or in the maturation of acces- 
sory cells. 
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